Hormone receptor-positive, HER2-negative early breast cancer
Research activity focuses on early breast cancer with hormone receptor positivity and HER2 negativity, particularly cases with a higher risk of recurrence and the need for closer long-term disease control.
- Recurrence risk
- Progression-free survival
- Overall survival
The sponsor is also involved in studies examining treatment persistence and outcomes in patients receiving endocrine-based and targeted approaches for this disease setting.
Advanced HER2-negative, hormone receptor-positive breast cancer
Clinical research includes advanced breast cancer in the first-line therapeutic setting, with attention to patients whose disease remains HER2-negative and hormone receptor-positive.
- Treatment response
- Objective response rate
- Residual disease control
These studies reflect an interest in therapeutic strategies that address disease burden, response durability, and clinical benefit in advanced settings.
HER2-negative metastatic breast cancer with homologous recombination repair alterations
The sponsor supports research in unresectable and metastatic breast cancer associated with BRCA1/2 and other DNA repair gene alterations, including homologous recombination deficiency.
- BRCA-associated disease
- DNA repair pathway defects
- Metastatic disease management
Research in this area centers on molecularly defined breast cancer populations with distinct therapeutic needs.
Treatment persistence and patient coaching in breast cancer care
One area of study addresses patient education and typology-based coaching to support sustained use of ribociclib therapy in breast cancer treatment.
- Treatment adherence
- Therapy continuation
- Patient support interventions
This research reflects a therapeutic interest in improving continuity of care during prolonged breast cancer treatment.
